Dengue vaccine: WHO position paper,September 2018 – Recommendations |
| |
| Institution: | 1. Department of Population Medicine, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman (UTAR), Jalan Sungai Long, Bandar Sungai Long, Cheras 43000 Kajang, Selangor, Malaysia;2. Department of Public Health, University of Dundee, Dundee, United Kingdom;3. Medical Affairs Department, Bayer Co. Malaysia Sdn. Bhd., Selangor, Malaysia;4. Department of Pre-clinical Sciences, Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman (UTAR), Jalan Sungai Long, Bandar Sungai Long, Cheras 43000 Kajang, Selangor, Malaysia;5. Department of Medical Microbiology and Parasitology, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia;1. Dengue Branch, Centers for Disease Control and Prevention, San Juan, PR, USA;2. United States Public Health Service, Silver Springs, MD, USA;3. Institute for Global Health and Translational Sciences and Department of Medicine, and Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, NY, USA;4. Department of Virology, Armed Forces Research Institute for Medical Sciences, Bangkok, Thailand;5. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, CA, USA;6. Department of Biology, University of Florida, Gainesville, FL, USA;7. Saw Swee Hock School of Public Health, National University of Singapore, Singapore;8. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK;9. Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, USA;1. Vaccination Value Modeling, Sanofi Pasteur, Lyon, France;2. MaIAGE, INRA, Université Paris-Saclay, 78350 Jouy-en-Josas, France;1. Research Institute for Tropical Medicine, Alabang, Muntinlupa City, Philippines;2. Pasteur Institute Ho Chi Minh City, Ho Chi Minh City, Vietnam;3. Department of Child Health, Medical School, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia;4. Pediatric Institute, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia;5. Queen Sirikit National Institute of Child Health, Bangkok, Thailand;6. Chong Hua Hospital, Cebu City Guadalupe Health Center Annex, Guadalupe, Cebu City, Philippines;7. Child Health Department, Hasan Sadikin Hospital–Faculty of Medicine, Padjadjaran University, Bandung, Indonesia;8. Department of Preventive Medicine, School of Medicine, Udayana University, Denpasar, Bali, Indonesia;9. Department of Paediatrics, Penang Hospital, Penang, Malaysia;10. Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand;11. Dengue Project Banpong-Photharam, Faculty of Tropical Medicine, Mahidol University, Ratchathewi, Bangkok, Thailand;12. Department of Virology, US Army Medical Component–Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), US Army Medical Component, Bangkok, Thailand;13. Sanofi Pasteur, Marcy-l''Étoile, France;14. Sanofi Pasteur, Makati City, Philippines;15. Sanofi Pasteur, Singapore, Singapore;p. Sanofi Pasteur, Swiftwater, PA, USA;q. Sanofi Pasteur, Lyon, France |
| |
| Abstract: | This article presents the World Health Organization’s (WHO) recommendations on the use of dengue vaccine excerpted from the WHO position paper on dengue vaccine – September 2018, published in the Weekly Epidemiological Record 1]. This position paper replaces the July 2016 WHO position paper concerning the first licensed dengue vaccine, CYD-TDV 2]. The position paper presents new evidence that became available in November 2017. A retrospective analysis of data from clinical trials, using a new serological assay classified trial participants according to their dengue serostatus prior to receipt of the first vaccine dose. The analysis revealed an excess risk of severe dengue in seronegative vaccine recipients compared to seronegative non-vaccinated individuals, while confirming long-term protection in seropositive individuals 3]. The paper provides revised guidance on dengue vaccination strategies from a population health perspective.Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of dengue vaccine CYD-TDV were discussed by SAGE in April 2018; evidence presented at the meeting can be accessed at: http://www.who.int/immunization/sage/meetings/2018/april/presentations_background_docs/en/ |
| |
| Keywords: | WHO position paper Vaccine position paper Dengue vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
